- Home
- INVE vs ASMB Comparison
INVE vs ASMB Comparison
Compare INVE & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- ASMB
- Stock Information
- Founded
- INVE 1990
- ASMB 2005
- Country
- INVE United States
- ASMB United States
- Employees
- INVE N/A
- ASMB N/A
- Industry
- INVE Computer peripheral equipment
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- ASMB Health Care
- Exchange
- INVE Nasdaq
- ASMB Nasdaq
- Market Cap
- INVE 74.2M
- ASMB 139.8M
- IPO Year
- INVE 1997
- ASMB 2010
- Fundamental
- Price
- INVE $3.50
- ASMB $18.75
- Analyst Decision
- INVE Strong Buy
- ASMB Strong Buy
- Analyst Count
- INVE 3
- ASMB 3
- Target Price
- INVE $6.50
- ASMB $33.00
- AVG Volume (30 Days)
- INVE 99.0K
- ASMB 43.5K
- Earning Date
- INVE 08-07-2025
- ASMB 08-07-2025
- Dividend Yield
- INVE N/A
- ASMB N/A
- EPS Growth
- INVE N/A
- ASMB N/A
- EPS
- INVE 3.12
- ASMB N/A
- Revenue
- INVE $25,239,000.00
- ASMB $32,154,000.00
- Revenue This Year
- INVE N/A
- ASMB $0.04
- Revenue Next Year
- INVE $9.00
- ASMB N/A
- P/E Ratio
- INVE $1.12
- ASMB N/A
- Revenue Growth
- INVE N/A
- ASMB 148.33
- 52 Week Low
- INVE $2.86
- ASMB $7.75
- 52 Week High
- INVE $4.35
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- INVE 63.68
- ASMB 65.84
- Support Level
- INVE $3.10
- ASMB $18.01
- Resistance Level
- INVE $3.61
- ASMB $18.99
- Average True Range (ATR)
- INVE 0.14
- ASMB 0.84
- MACD
- INVE 0.04
- ASMB -0.05
- Stochastic Oscillator
- INVE 79.25
- ASMB 84.42
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.